Business Wire

TEJ-KOHLI-FOUNDATION

Share
5,736 of the World’s Poorest People Received the Gift of Sight in 2019 at the Tej Kohli Cornea Institute

On the fourth anniversary of the Tej Kohli Cornea Institute in Hyderabad, the Tej Kohli Foundation has renewed its commitment of $14m of funding from 2020. During 2019 5,736 individuals were cured of blindness or severe visual impairment at The Tej Kohli Cornea Institute, which is a collaboration between the Tej Kohli Foundation in London, and the LV Prasad Eye Institute in Hyderabad, a World Health Organization Collaborating Centre.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005417/en/

The Tej Kohli Cornea Institute was inaugurated in December 2015 to tackle the problem of poverty blindness by providing free treatment to anyone who needs it. Since its inauguration the Cornea Institute has taken care of 223,404 outpatients, completed 43,255 surgical procedures, collected 38,225 donor corneas into its eye bank, utilized 22,176 donor corneas, trained 152 clinicians, published 202 papers and given 892 educational presentations.

Reaching people living with blindness and severe visual impairment in the hard-to-reach rural areas where 66% of Indians live is a particular challenge that the Tej Kohli Cornea Institute is uniquely solving. A unique presence of eye care centres in villages supplemented with a fully equipped mobile diagnostics van take eye care directly to hard-to-reach patients, with more than 100 corneal transplants completed so far in these rural areas.

Other 2019 operational highlights at the Tej Kohli Cornea Institute included:

  • 280,000 individuals called the ‘Call Netra’ toll free eye care helpline.
  • A special privilege ‘Keratoplasty card’ was issued to corneal transplant patients to ensure priority check-ups and access to care anytime and anywhere.
  • An education app was launched to continually assess cornea doctors in their evaluations.
  • The ECHO project linked expert specialist teams with clinicians in remote local communities.

According to the World Health Organisation, 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. 14m live in India, where between 6m and 7m people are currently waiting for a corneal transplant. At least 300,000 children in India have some form of severe visual impairment or blindness.

Whilst approximately 75% of corneal disease is curable, the costs of corneal transplantation surgery using donor cornea, and the many years of medicine needed to prevent rejection, makes treatment inaccessible to many. Born out of a partnership with the LV Prasad Eye Institute and the Tej Kohli Foundation, the Tej Kohli Cornea Institute is focussed on prevention, treatment and cure at no cost directly into these high-impact populations that are living needlessly with corneal blindness.

Dr Pravin K Vaddavalli, MD, Director of Tej Kohli Cornea Institute said:

“The last four years have been an opportunity to assess the magnitude of the problem of corneal blindness, create strategic partnerships to expand our reach and start to evolve ways and means to allow these patients to live longer, more productively and with dignity.”

Wendy Kohli, co-Founder of the Tej Kohli Foundation said:

“It’s an uncomfortable reality that millions of people worldwide are living with curable blindness that persists entirely because they cannot afford to access treatment. The impact of restoring a person’s vision on that person’s confidence, wellbeing and economic prospects is substantial. Through the Tej Kohli Cornea Institute we are able to make direct interventions into individual lives that help and transform entire families every single day.”

---

About The Tej Kohli Cornea Institute

The mission of the Tej Kohli Cornea Institute is to prevent, control and eliminate corneal blindness worldwide. The Institute is a global leader in research and development, preventative medicine, education and cornea transplants. The Institute enables access to affordable treatment through systemic long-term efforts to create widespread access to high-quality eye care facilities that are delivered by people with the resources, technical skills and compassion to handle diverse population segments.

http://www.tejkohlicorneainstitute.com

About LV Prasad Eye Institute

Established in 1987, the LV Prasad Eye Institute (LVPEI), a World Health Organization Collaborating Centre for Prevention of Blindness, is a comprehensive eye health facility. The Institute has ten active arms to its areas of operations: Clinical Services, Education, Research, Vision Rehabilitation, Rural and Community Eye Health, Eye Banking, Advocacy and Policy Planning, Capacity Building, Innovation and Product Development. LVPEI's mission is to provide equitable and quality eye care to all sections of society.

http://www.lvpei.org

About the Tej Kohli Foundation

Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness worldwide. Since 2015 the Foundation has funded the provision of corneal transplants in underserved communities in India through the Tej Kohli Cornea Institute; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness. In December 2019 the Foundation launched the ‘Future Bionics’ program to gift 3D printed bionic arms to children and young people who are living with limb difference in the United Kingdom.

http://www.tejkohlifoundation.com

END

Social Media:

https://www.facebook.com/TejKohliFoundation/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales Launches AI Security Fabric, Providing AI Runtime Security for Agentic AI and LLM-Powered Applications11.12.2025 09:00:00 CET | Press release

Thales launches its new AI Security Fabric, delivering the first runtime security capabilities designed to protect Agentic AI, LLM-powered applications, enterprise data, and identities.New capabilities address emerging AI-specific threats—including prompt injection, data leakage, model manipulation, and insecure RAG pipelines—helping organizations innovate safely while maintaining compliance.With upcoming 2026 enhancements, Thales aims to provide a comprehensive security layer for AI ecosystems, enabling enterprises to confidently scale AI adoption across cloud and on-premises environments. AI is one of the fastest-growing technologies in the history of modern business, with the ability to revolutionize industries, optimize operations, and drive innovation, but it is also introducing security gaps, risks, and vulnerabilities. According to McKinsey, 78% of organizations are using AI in at least one business function, up from 55% two years ago. As a result, 73% of them are investing in A

Interactive Brokers Adds Access to Brazil’s B3 Exchange11.12.2025 09:00:00 CET | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that eligible clients outside of Brazil can now trade Brazilian equities through B3, the Brazil Stock Exchange. This expansion gives investors more ways to access emerging market opportunities across Latin America alongside global stocks, options, futures, currencies, bonds, funds, and more through a single unified platform. The B3 Exchange is one of the most active and liquid markets in the region. With this addition, investors will have direct access to trade Brazilian equities, plus over 160 markets worldwide using Interactive Brokers’ powerful trading platforms and tools. “Global investors need seamless access to diverse markets to stay competitive,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “By adding Brazil’s B3 Exchange, we’re giving our clients efficient, low-cost access to one of the world’s most dynamic emerging economies through our unified global platform.” Int

Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman11.12.2025 08:30:00 CET | Press release

Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026Announcement Follows Year of Dual CEO / COO Model and Returns Company to Single Leader Structure Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO for Kyowa Kirin, current CEO Masashi Miyamoto, Ph.D., remains Chairman. In March 2025, shareholders approved a dual CEO / COO model, with Mullick appointed to the newly created role of Chief Operating Officer, partnering with Miyamoto to lead the global organisation. The model provided a transition period for Mullick

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin11.12.2025 07:00:00 CET | Press release

Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause and is associated with very high burden of disease due to severe itch, sleep deprivation and mental distress1 Galderma’s phase II study builds on emerging research that reinforces the role of IL-31 – a neuroimmune cytokine that is involved in driving itch – in CPUO1 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-312 It is approved by multiple regulatory authorities for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis – conditions in which IL-31 plays a key role in driving itch, inflammation, epidermal dysregulation, and, in prurigo nodularis, fibrosis2-6 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic P

Ant International and HSBC Test New Cross-Border Payments Solution Using Tokenised Deposits on Swift’s Network and Powered by ISO 2002211.12.2025 04:00:00 CET | Press release

ISO 20022-enabled solution allows blockchain interoperability on Swift’s network, using Ant International’s technology and HSBC’s Tokenised Deposit Service Integration with Swift’s network extends AML and anti-fraud capabilities to tokenised deposits transactions Proof of concept (POC) marks a step towards enabling seamless money movement across borders Ant International, HSBC and Swift today have completed a successful Proof of Concept (POC) for the cross-border transfer of tokenised deposits using ISO 20022 standards. The initiative leverages Swift’s global messaging network and HSBC’s recently launched Tokenised Deposit Service, combined with Ant International’s blockchain technology. The POC marks a key milestone in Ant International, HSBC, and Swift’s efforts to help businesses unlock the full benefits of tokenisation for enhanced liquidity, programmable finance, and 24/7 real-time settlement. As part of this initiative, Ant International and HSBC successfully integrated Ant Inter

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye